Markets · Asia · KSE

128940.KS Hanmi Pharm

₩480,500 -10.02%

Asia · Health Care

Log

Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.

-10.02%

YTD

+35.50%

P/E

—

P/B

—

ROE

—

Div yield

—

Beta

0.94

Market cap

—

RSI (14)

Next earnings

—

Previous session

close of Oct 8, 2026 · EOD, no live order book

Open

₩526,000

₩480,500

VWAP (n/a)

—

Day high

₩526,000

Day low

₩475,000

Volume

274K

VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.

Latest headlines

MegazoneCloud Begins Building Hanmi Pharmaceutical's Quality Assurance AI Agent with 'AIR Studio'

Yahoo Finance · Sep 11

Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate

Yahoo Finance · Aug 24

Roche commits to lean-mass preservation with Hanmi obesity deal

Yahoo Finance · Aug 24

Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

Yahoo Finance · Aug 24

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Yahoo Finance · Jun 16

Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations

Yahoo Finance · Jun 3

Headlines via Yahoo Finance · links open the source · not an endorsement.

Research & reports

TradingView ↗

Charts & analysis

Yahoo Finance ↗

Quote & news

External resources — availability and opinions are theirs, not ours.

This is reference data for your own analysis — not a recommendation to buy or sell 128940.KS. Try it in the Lab to size a position and see the risk.